<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351376</url>
  </required_header>
  <id_info>
    <org_study_id>10-00923</org_study_id>
    <nct_id>NCT01351376</nct_id>
  </id_info>
  <brief_title>LLLT Combined With CDT in Breast Cancer-Related Lymphedema</brief_title>
  <official_title>The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the effects of Low Level Laser Therapy (LLLT) on breast
      cancer-related lymphedema when utilized in conjunction with Complex Decongestive Therapy
      (CDT) when compared to CDT treatment alone. The investigators hypothesize that the addition
      of LLLT to CDT will result in statistically significant improvements and greater long-term
      benefits as measured by changes in arm volume and quality of life when compared to the
      benefits of CDT alone for the treatment of breast cancer-related lymphedema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm Volume</measure>
    <time_frame>13 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey (SF-36)</measure>
    <time_frame>13 months</time_frame>
    <description>Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. The individual question items (Likert scale 0-4) are first summed for each item under the various sections. Then, those summary scores are then standardized on a scale between 0 and 1 using the mean and standard deviation of the actual scores and finally, weighted to a scale between 0 and 100. The items contributing to a scale are scored so that a higher score represents better health, and they are averaged together to create the scale score. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CDT + inactive LLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LLL combined with CDT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CDT + active LLL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Level Laser Therapy</intervention_name>
    <description>Placebo LLL combined with CDT</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Low Level Laser</other_name>
    <other_name>Complex Decongestive Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low Level Laser</intervention_name>
    <description>Active LLL combined with CDT</description>
    <arm_group_label>LLL combined with CDT</arm_group_label>
    <other_name>Complex Decongestive Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node
             dissection (sentinel biopsy or axillary dissection)

          -  stage II or III unilateral secondary upper extremity lymphedema (as defined by the
             International Society of Lymphology)

          -  girth ≥ 2 cm circumferential difference and/or volume ≥ 200 mL compared to the
             uninvolved upper extremity at any 4 cm segment

          -  able to commit to a long term follow-up schedule

        Exclusion Criteria:

          -  active cancer/metastatic cancer

          -  currently receiving or have plans for adjuvant radiation or chemotherapy

          -  pregnant

          -  presence of other extremity lymphedema (primary or secondary)

          -  pacemaker

          -  artificial joints in the upper quadrants

          -  renal failure

          -  arterial insufficiency

          -  congestive heart failure

          -  chronic inflammatory conditions

          -  history of deep vein thrombosis (DVT) in the lymphedematous upper extremity

          -  previous treatment with Low Level Laser (regardless of indication)

          -  medication(s) known to affect body fluid balance

          -  body mass index (BMI) &gt; 40 (morbid obesity)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teresa Denham, PT, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Rusk Institute of Rehabilitation Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Rusk Institute of Rehabilitation Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tisch Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <results_first_submitted>December 5, 2017</results_first_submitted>
  <results_first_submitted_qc>September 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2019</results_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphedema, Low Level Laser, Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
    <mesh_term>Breast Cancer Lymphedema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>CDT + inactive LLL
Low Level Laser Therapy: Placebo LLL combined with CDT</description>
        </group>
        <group group_id="P2">
          <title>LLL Combined With CDT</title>
          <description>CDT + active LLL
Low Level Laser: Active LLL combined with CDT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>CDT + inactive LLL
Low Level Laser Therapy: Placebo LLL combined with CDT</description>
        </group>
        <group group_id="B2">
          <title>LLL Combined With CDT</title>
          <description>CDT + active LLL
Low Level Laser: Active LLL combined with CDT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Arm Volume</title>
        <time_frame>13 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>CDT + inactive LLL
Low Level Laser Therapy: Placebo LLL combined with CDT</description>
          </group>
          <group group_id="O2">
            <title>LLL Combined With CDT</title>
            <description>CDT + active LLL
Low Level Laser: Active LLL combined with CDT</description>
          </group>
        </group_list>
        <measure>
          <title>Arm Volume</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.01"/>
                    <measurement group_id="O2" value="1.58" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form Health Survey (SF-36)</title>
        <description>Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. The individual question items (Likert scale 0-4) are first summed for each item under the various sections. Then, those summary scores are then standardized on a scale between 0 and 1 using the mean and standard deviation of the actual scores and finally, weighted to a scale between 0 and 100. The items contributing to a scale are scored so that a higher score represents better health, and they are averaged together to create the scale score. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
        <time_frame>13 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>CDT + inactive LLL
Low Level Laser Therapy: Placebo LLL combined with CDT</description>
          </group>
          <group group_id="O2">
            <title>LLL Combined With CDT</title>
            <description>CDT + active LLL
Low Level Laser: Active LLL combined with CDT</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form Health Survey (SF-36)</title>
          <description>Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health. The individual question items (Likert scale 0-4) are first summed for each item under the various sections. Then, those summary scores are then standardized on a scale between 0 and 1 using the mean and standard deviation of the actual scores and finally, weighted to a scale between 0 and 100. The items contributing to a scale are scored so that a higher score represents better health, and they are averaged together to create the scale score. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5085" spread="16.07351"/>
                    <measurement group_id="O2" value="72.6042" spread="18.01269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>CDT + inactive LLL
Low Level Laser Therapy: Placebo LLL combined with CDT</description>
        </group>
        <group group_id="E2">
          <title>LLL Combined With CDT</title>
          <description>CDT + active LLL
Low Level Laser: Active LLL combined with CDT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tara Denham, MD</name_or_title>
      <organization>Rehabilitation Medicine, New York University School of Medicine</organization>
      <phone>212 263 8240</phone>
      <email>Tara.Denham@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

